Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.61 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.61 |
| ▸ | BRAF | P15056 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.47 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584583 | 0.86 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL8860384 | 0.84 | BRAF (0.44) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL4586656 | 0.83 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL4586325 | 0.81 | MAPK13 (0.58) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL4585385 | 0.79 | ALOX5 (0.62) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL4552211 | 0.79 | ALOX5 (0.67) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL4585778 | 0.78 | MAPK13 (0.49) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL4585076 | 0.78 | MAPK13 (0.57) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL4585395 | 0.77 | ALOX5 (0.61) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL8860156 | 0.76 | BRAF (0.41) | MAPK14MAPK13MAPK12MAPK11BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1545535-A4 | TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE | SCIOS INC (US) | 2008-06-04 | — | — | EP | disclosed |
| EP-1583535-A4 | METHODS FOR TREATING DIABETES | SCIOS INC (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1583535-A2 | METHODS FOR TREATING DIABETES | SCIOS INC. (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1545535-A2 | TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE | SCIOS INC. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005030091-A2 | STENTS AND INTRA-LUMINAL PROSTHESES CONTAINING MAP KINASE INHIBITORS | SCIOS INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2004053107-A2 | METHODS FOR TREATING DIABETES | SCIOS INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004021988-A2 | TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE | SCIOS INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| US-5670527-A | CYTOKINE INHIBITORS USEFUL IN TREATING ASTHMA, OSTEOPOROSIS, ARTHRITIS, INFLAMMATION, SEPSIS, CARDIOVASCULAR DISORDERS, DIABETES, MULTIPLE SCLEROSIS, SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |